Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shelley Niwa is active.

Publication


Featured researches published by Shelley Niwa.


International Journal of Cancer | 1996

International renal cell cancer study. VII. role of diet

Alicja Wolk; Gloria Gridley; Shelley Niwa; Per Lindblad; Margaret McCredie; Anders Mellemgaard; Jack S. Mandel; Jürgen Wahrendorf; Joseph K. McLaughlin; Hans-Olov Adami

We investigated the role of diet in the etiology of renal cell cancer (RCC) in a multi‐center, population‐based case‐control study conducted in Australia, Denmark, Sweden and the United States, using a shared protocol. A total of 1,185 incident histopathologically confirmed cases (698 men, 487 women) and 1,526 controls (915 men, 611 women) frequency‐matched to cases by sex and age were included in the analyses. The association between RCC and diet was estimated by relative risks (RR) and 95% confidence intervals (CI) adjusted for age, sex, study center, body mass index and smoking. A statistically significant positive association was observed for total energy intake (RR = 1.7, 95% CI = 1.4–2.2 for the highest vs. lowest quartile, p value for trend <0.00001), while the hypothesis that protein and fat are risk factors independent of energy was not supported. Fried meats were associated with increased RCC risk, while vegetables and fruits were protective, with the strongest effect observed for the highest quartile of consumption of orange/dark green vegetables but not vitamin C or β carotene. Increased risk was associated with low intake (lowest decile) of vitamin E and magnesium. We observed an apparent protective effect of alcohol confined to women and probably due to chance. Our findings indicate an important role of nutrition in the development of RCC. The apparent positive association of energy intake with risk of RCC needs further investigation in a prospective cohort study to exclude the possible impact of differences in recall between cases and controls.


British Journal of Cancer | 2007

Gallstones and the risk of biliary tract cancer: a population-based study in China.

Ann W. Hsing; Y. T. Gao; T. Q. Han; Asif Rashid; Lori C. Sakoda; Bingsheng Wang; Ming-Chang Shen; Bai He Zhang; Shelley Niwa; Jinbo Chen; Joseph F. Fraumeni

We conducted a population-based study of 627 patients with biliary tract cancers (368 of gallbladder, 191 bile duct, and 68 ampulla of Vater), 1037 with biliary stones, and 959 healthy controls randomly selected from the Shanghai population, all personally interviewed. Gallstone status was based on information from self-reports, imaging procedures, surgical notes, and medical records. Among controls, a transabdominal ultrasound was performed to detect asymptomatic gallstones. Gallstones removed from cancer cases and gallstone patients were classified by size, weight, colour, pattern, and content of cholesterol, bilirubin, and bile acids. Of the cancer patients, 69% had gallstones compared with 23% of the population controls. Compared with subjects without gallstones, odds ratios associated with gallstones were 23.8 (95% confidence interval (CI), 17.0–33.4), 8.0 (95% CI 5.6–11.4), and 4.2 (95% CI 2.5–7.0) for cancers of the gallbladder, extrahepatic bile ducts, and ampulla of Vater, respectively, persisting when restricted to those with gallstones at least 10 years prior to cancer. Biliary cancer risks were higher among subjects with both gallstones and self-reported cholecystitis, particularly for gallbladder cancer (OR=34.3, 95% CI 19.9–59.2). Subjects with bile duct cancer were more likely to have pigment stones, and with gallbladder cancer to have cholesterol stones (P<0.001). Gallstone weight in gallbladder cancer was significantly higher than in gallstone patients (4.9 vs 2.8 grams; P=0.001). We estimate that in Shanghai 80% (95% CI 75–84%), 59% (56–61%), and 41% (29–59%) of gallbladder, bile duct, and ampulla of Vater cancers, respectively, could be attributed to gallstones.


International Journal of Cancer | 1996

International renal-cell-cancer study. VI. The role of medical and family history

Brigitte Schlehofer; Wolfgang Pommer; Anders Mellemgaard; John H. Stewart; Margaret McCredie; Shelley Niwa; Per Lindblad; Jack S. Mandel; Joseph K. McLaughlin; Jürgen Wahrendorf

A number of medical conditions have been linked with renal‐cell cancer, although the evidence is not consistent in every case. In a large international case‐control study of renal‐cell cancer, we examined, among other hypotheses, associations with a personal history of certain medical conditions and a family history of cancer of the kidney or thyroid. Relative risks (RR), adjusted for the effects of age, gender, body‐mass index, tobacco smoking and study centre, were significantly increased by a history of kidney stones or thyroid or kidney disease. The RR were not altered by additional adjustment for hypertension, or when diagnoses were restricted to those made at least 5 or 10 years before 1987 (the usual “cut‐off” date). The link with kidney injury is particularly likely to be affected by recall bias. Increased RR of borderline significance were found for kidney infection (RR, 1.2) and diabetes (RR, 1.4). Having one first‐degree relative with kidney cancer was associated with a significantly increased risk of renal‐cell cancer (RR, 1.6; 95% Cl, 1.1–2.4). Seven cases reported 2 first‐degree relatives with kidney cancer. No controls had first‐degree relatives with kidney cancer. None of our participants reported having von Hippel‐Lindau disease. The data suggests that a few conditions of the kidney are strongly associated with renal‐cell cancer and that heredity plays a role in a small proportion of cases.


International Journal of Cancer | 2007

Hepatitis B and C virus infection and the risk of biliary tract cancer: A population‐based study in China

Ann W. Hsing; Mingdong Zhang; Asif Rashid; Katherine A. McGlynn; Bing Shen Wang; Shelley Niwa; Betty A. Ortiz-Conde; James J. Goedert; Joseph F. Fraumeni; Thomas R. O'Brien; Yu-Tang Gao

Emerging data suggest that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections may also play a role in extrahepatic bile duct cancers. To test the HBV hypothesis, we examined the relationship of HBV/HCV infection with risks of biliary tract cancer and biliary stones in a population‐based case‐control study conducted in Shanghai, China. Standard assays were used to detect HBV surface antigen (HBsAg) and antibodies against HBV core antigen (anti‐HBc) and hepatitis C virus (anti‐HCV) in sera from 417 patients with biliary tract cancers, 517 with biliary stones, and 762 healthy controls randomly selected from the population. Unconditional logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for each disease type. HBsAg seroprevalence was 7.3% among population controls and 14.2% among patients with extrahepatic bile duct cancer, resulting in a 2.4‐fold risk of extrahepatic bile duct cancer (95% CI 1.2–4.5). No association was found for cancers of the gallbladder (prevalence 8.2%) or the ampulla of Vater (6.1%), or for stones in the gallbladder (10.1%) or bile duct (9.3%). Further adjustment for education, smoking, body mass index, diabetes and gallstones did not materially change the results. Prevalence of HCV infection in this population was low (2%), limiting our ability to detect an association with biliary diseases. In Shanghai, an HBV endemic area, chronic HBV infection was associated with a 2.4‐fold risk of extrahepatic bile duct cancer. These results should be confirmed in other populations with varying risks of HBV and HCV infection.


Cancer Research | 2008

Variants in Inflammation Genes and the Risk of Biliary Tract Cancers and Stones: A Population-Based Study in China

Ann W. Hsing; Lori C. Sakoda; Asif Rashid; Gabriella Andreotti; Jinbo Chen; Bin Shen Wang; Ming Chang Shen; Bingshu E. Chen; Philip S. Rosenberg; Mingdong Zhang; Shelley Niwa; Lisa Chu; Robert Welch; Meredith Yeager; Joseph F. Fraumeni; Yu-Tang Gao; Stephen J. Chanock

To evaluate the role of chronic inflammation in the development of gallstones and biliary tract cancer, we examined the risk associated with 62 single nucleotide polymorphisms (SNPs), in 22 inflammation-related genes, in a population-based case-control study conducted in Shanghai, China, where the incidence of biliary tract cancer has been increasing in recent decades. The study included 411 cases with biliary tract cancer (237 gallbladder, 127 extrahepatic bile duct, and 47 ampulla of Vater), 895 with biliary stones, and 786 controls randomly selected from the population. Unconditional logistic regression was used to calculate odds ratios and 95% confidence intervals for the association of individual SNPs and haplotypes with biliary stones and biliary tract cancer. Of the 62 SNPs examined, 14 were related to the risk of biliary cancer and stones. Specifically, variants in the IL8, IL8RB, RNASEL, and NOS2 genes were associated with biliary stones, whereas VEGF variants were associated with gallbladder cancer. Of the 10 genes with multiple SNPs from which we inferred haplotypes, only one IL8RB haplotype, consisting of 3 SNPs (rs2230054, rs1126579, and rs1126580), was associated with the risk of bile duct cancer (P = 0.003) and biliary stones (P = 0.02), relative to the most frequent haplotype. In summary, common variants in genes that influence inflammatory responses may predispose to gallstones and biliary tract cancer, suggesting the need for future studies into the immunologic and inflammatory pathways that contribute to biliary diseases, including cancer.


Preventive Medicine | 2011

Comparative community outreach to increase cervical cancer screening in the Mississippi Delta

Philip E. Castle; Alfio Rausa; Tameka Walls; Patti E. Gravitt; Edward E. Partridge; Vanessa Olivo; Shelley Niwa; Kerry Grace Morrissey; Laura Tucker; Hormuzd A. Katki; Isabel C. Scarinci

OBJECTIVE The aim of the study was to increase participation in cervical cancer screening of under-screened women living in the Mississippi Delta, a U.S. population at high risk for cervical cancer. METHODS We conducted a door-to-door feasibility study of women living in the Mississippi Delta to increase participation in cervical cancer screening in 2009-10. Women (n=119) aged 26-65 years who had not been screened in last 3 years or more, were not pregnant, and had a cervix were offered a cost-free choice: clinic-based Pap testing or home self-collection with HPV DNA testing. RESULTS Seventy-seven women (64.7%) chose self-collection with HPV testing, of which sixty-two (80.5%) returned their self-collected specimen. By comparison, 42 women (35.3%) chose Pap testing, of which 17 (40.5%) attended their clinic appointment. Thus there was an almost 4-fold greater participation of under-screened women in self-collection with HPV testing than in free Pap testing (78.4% vs. 21.5%). CONCLUSIONS We found that offering self-collection will increase participation in cervical cancer screening among under-screened populations living in the Mississippi Delta. Based on these preliminary results, we suggest that self-collection with HPV DNA testing might complement current Pap testing programs to reach under-screened populations of women, such as those living in the Mississippi Delta.


Nature Communications | 2015

Two susceptibility loci identified for prostate cancer aggressiveness

Sonja I. Berndt; Zhaoming Wang; Meredith Yeager; Michael C. R. Alavanja; Demetrius Albanes; Laufey Amundadottir; Gerald L. Andriole; Laura E. Beane Freeman; Daniele Campa; Geraldine Cancel-Tassin; Federico Canzian; Jean-nicolas Cornu; Olivier Cussenot; W. Ryan Diver; Susan M. Gapstur; Henrik Grönberg; Christopher A. Haiman; Brian E. Henderson; Amy Hutchinson; David J. Hunter; Timothy J. Key; Suzanne Kolb; Stella Koutros; Peter Kraft; Loic Le Marchand; Sara Lindström; Mitchell J. Machiela; Elaine A. Ostrander; Elio Riboli; Fred Schumacher

Most men diagnosed with prostate cancer will experience indolent disease; hence discovering genetic variants that distinguish aggressive from non-aggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49×10-9) and rs78943174 at 3q26.31 (NAALADL2, P=4.18×10-8). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85×10-5) with no association for non-aggressive prostate cancer compared to controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.


Fertility and Sterility | 2013

Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort

Britton Trabert; Emmet J. Lamb; Bert Scoccia; Kamran S. Moghissi; Carolyn Westhoff; Shelley Niwa; Louise A. Brinton

OBJECTIVE To examine the relationship of ovulation-inducing drugs and ovarian cancer. DESIGN Retrospective cohort study, with additional follow-up since initial report. SETTING Five large reproductive endocrinology practices. PATIENT(S) In a retrospective cohort of 9,825 women evaluated for infertility at five clinical sites in the United States between 1965 and 1988 with follow-up through 2010, we examined the relationship of ovulation-inducing drugs and ovarian cancer (n = 85). INTERVENTION(S) None. MAIN OUTCOME MEASURE(S) Hazard rate ratios (RR) and 95% confidence intervals (CI) for ovarian cancer. RESULT(S) Among women evaluated for infertility, there was no association of ovarian cancer risk with ever use of clomiphene citrate (CC) (adjusted RR 1.34, 95% CI 0.86-2.07) or gonadotropins (RR 1.00, 95% CI 0.48-2.08) and no evidence that any of several more detailed subgroups of usage were related to an increased risk with one exception: women who used CC and remained nulligravid did demonstrate much higher risks than those who successfully conceived compared with nonusers (respectively, RR 3.63, 95% CI 1.36-9.72 vs. RR 0.88, 95% CI 0.47-1.63). CONCLUSION(S) Our overall results were reassuring and consistent with other studies. A reason for an association between CC use and ovarian cancer among persistently nulligravid women remains to be determined. Given the large and increasing number of women treated with ovulation-inducing drugs, the increased risk of ovarian cancer among the subset of women who remained nulligravid should be further monitored.


International Journal of Cancer | 2007

Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China

Ann W. Hsing; Yu-Tang Gao; Katherine A. McGlynn; Shelley Niwa; Mingdong Zhang; Tian Quan Han; Bing Sheng Wang; Jinbo Chen; Lori C. Sakoda; Ming Chang Shen; Bai He Zhang; Jie Deng; Asif Rashid

Biliary tract cancers are relatively rare but fatal tumors. Apart from a close link with gallstones and cholangitis, risk factors for biliary tract cancer are obscure. Chronic liver conditions, including liver cirrhosis, have been linked to a higher risk of biliary tract cancer. In a population‐based case‐control study conducted in Shanghai, China, we investigated the relationships of a history of chronic hepatitis and liver cirrhosis as well as a family history of liver cancer with biliary tract cancer risk. The study included 627 patients with biliary tract cancers (368 gallbladder, 191 bile duct and 68 ampulla of Vater), 1,037 patients with biliary stones (774 gallbladder stones and 263 bile duct stones) and 959 healthy subjects randomly selected from the population. Bile duct cancer was associated with self‐reports of chronic liver conditions, including a history of chronic hepatitis (OR = 2.0, 95% CI 0.9–4.4), liver cirrhosis (OR = 4.7, 95% CI 1.9–11.7) and a family history of primary liver cancer (OR = 2.0, 95% CI 1.0–3.9). The excess risk persisted after adjustment for gallstones and were more pronounced among subjects without gallstones (OR = 5.0, 95% CI 1.3–20.0 and OR = 4.9, 95% 2.0–12.2, respectively). History of liver conditions was also associated with an excess of biliary stones (OR = 1.9, 95% CI 1.2–3.0). No association was found for cancers of the gallbladder and ampulla of Vater. A history of chronic hepatitis and cirrhosis may be risk factors for extraheptic bile duct cancer. Given that chronic infection with hepatitis B virus (HBV) is the most common cause of liver disease in China, serologic markers of HBV need to be measured in future studies to examine the link between HBV and bile duct cancer.


Human Molecular Genetics | 2015

Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions

Ying Han; Dennis J. Hazelett; Fredrik Wiklund; Fredrick R. Schumacher; Daniel O. Stram; Sonja I. Berndt; Zhaoming Wang; Kristin A. Rand; Robert N. Hoover; Mitchell J. Machiela; M. Yeager; Laurie Burdette; Charles C. Chung; Amy Hutchinson; Kai Yu; Jianfeng Xu; Ruth C. Travis; Timothy J. Key; Afshan Siddiq; Federico Canzian; Atsushi Takahashi; Michiaki Kubo; Janet L. Stanford; Suzanne Kolb; Susan M. Gapstur; W. Ryan Diver; Victoria L. Stevens; Sara S. Strom; Curtis A. Pettaway; Ali Amin Al Olama

Interpretation of biological mechanisms underlying genetic risk associations for prostate cancer is complicated by the relatively large number of risk variants (n = 100) and the thousands of surrogate SNPs in linkage disequilibrium. Here, we combined three distinct approaches: multiethnic fine-mapping, putative functional annotation (based upon epigenetic data and genome-encoded features), and expression quantitative trait loci (eQTL) analyses, in an attempt to reduce this complexity. We examined 67 risk regions using genotyping and imputation-based fine-mapping in populations of European (cases/controls: 8600/6946), African (cases/controls: 5327/5136), Japanese (cases/controls: 2563/4391) and Latino (cases/controls: 1034/1046) ancestry. Markers at 55 regions passed a region-specific significance threshold (P-value cutoff range: 3.9 × 10(-4)-5.6 × 10(-3)) and in 30 regions we identified markers that were more significantly associated with risk than the previously reported variants in the multiethnic sample. Novel secondary signals (P < 5.0 × 10(-6)) were also detected in two regions (rs13062436/3q21 and rs17181170/3p12). Among 666 variants in the 55 regions with P-values within one order of magnitude of the most-associated marker, 193 variants (29%) in 48 regions overlapped with epigenetic or other putative functional marks. In 11 of the 55 regions, cis-eQTLs were detected with nearby genes. For 12 of the 55 regions (22%), the most significant region-specific, prostate-cancer associated variant represented the strongest candidate functional variant based on our annotations; the number of regions increased to 20 (36%) and 27 (49%) when examining the 2 and 3 most significantly associated variants in each region, respectively. These results have prioritized subsets of candidate variants for downstream functional evaluation.

Collaboration


Dive into the Shelley Niwa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joseph K. McLaughlin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph F. Fraumeni

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kai Yu

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Michael B. Cook

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge